Effectiveness of Live Motile Sperm Sorting Device on IVF Outcomes in Advanced Paternal Age (IVF)
Evaluation of the Effectiveness of Live Motile Sperm Sorting Device on In Vitro Fertilization Outcomes in Advanced Paternal Age Group
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Male infertility contributes to approximately 50% of all infertility cases. One of the essential steps in assisted reproductive technology (ART) is sperm preparation, which aims to select motile, morphologically normal spermatozoa with minimal DNA damage. However, conventional sperm preparation techniques involving centrifugation may increase oxidative stress and sperm DNA fragmentation. The live motile sperm sorting device LensHooke® CA0 has been proposed as an alternative to traditional density gradient centrifugation (DGC), aiming to reduce sperm damage and potentially improve IVF outcomes.
LensHooke® CA0 offers several advantages: it avoids centrifugation and the mechanical stress associated with it; optimally reduces the DNA fragmentation index (DFI); minimizes the risk of premature acrosome reaction (AR); is suitable for both normozoospermic and non-normozoospermic semen samples; simplifies workflow (only three pipetting steps required: loading, medium addition, and recovery); and ensures a high degree of standardization, reducing inter-technician variability.
Moreover, paternal age is an important factor influencing sperm quality and fertility potential. Studies have demonstrated that men over 40 years of age exhibit higher sperm DNA fragmentation rates, increased morphological and motility abnormalities, and are associated with a higher incidence of embryonic chromosomal abnormalities and reduced live birth rates. Therefore, this population particularly requires optimized sperm selection methods to improve IVF/ICSI outcomes.
This study aims to evaluate the clinical value of this device through two primary objectives:
- To compare sperm quality post-processing and the DNA fragmentation index between the CA0 method and the conventional DGC method in advanced paternal age group.
- To compare the rates of blastocyst formation, euploid embryos, and clinical pregnancy between the two sperm preparation techniques in advanced paternal age group.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Son The Trinh
- Telefonnummer: + 84 902150873
- E-Mail: trinhtheson@vmmu.edu.vn
Studienorte
-
-
Ha Dong
-
Hà Nội, Ha Dong, Vietnam, 100000
- Rekrutierung
- Vietnam Military medical university
-
Kontakt:
- Phuong Minh Nguyen, M.D
- Telefonnummer: 0963048428
- E-Mail: nguyenminhphuongk53@vmmu.edu.vn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Male partners aged ≥ 40 years
- Semen analysis: volume ≥ 1.4 mL, sperm concentration ≥ 6 million/mL, progressive motility (PR) ≥ 20% after 3-5 days of abstinence.
- Female partners with ≥ 5 mature (MII) oocytes retrieved.
- Couples undergoing ICSI with PGT-A and elective single embryo transfer (eSET).
- Willingness to participate and sign informed consent.
Exclusion Criteria:
- Azoospermia, surgical sperm retrieval, or use of cryopreserved sperm.
- Female uterine or ovarian conditions severely affecting IVF outcomes.
- Use of donor sperm or donor oocytes
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Study group (CA0)
Sperm preparation using LensHooke® CA0 live motile sperm sorting device.
|
Sperm will be processed using the CA0 device by loading 1.0 mL of semen into the lower chamber and adding 0.9 mL of pre-equilibrated sperm washing medium into the upper chamber. The device is incubated at 37 °C for a minimum of 30 minutes, followed by aspirating 0.5 mL of recovered sperm suspension for ICSI. |
|
Aktiver Komparator: Control group (DGC)
Conventional sperm preparation using density gradient centrifugation.
|
Sperm will be prepared by layering 1 mL of 45% medium and 1 mL of 90% medium with 1 mL of semen sample. This is followed by a first centrifugation at 1500 rpm for 15 minutes, a wash step using 2 mL G-IVF plus medium, and a second centrifugation at 1200 rpm for 10 minutes to retain 0.5 mL of the sperm suspension. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Clinical Pregnancy Rate after single embryo transfer
Zeitfenster: 4 to 6 weeks after embryo transfer
|
Confirmed by the presence of an intrauterine gestational sac on ultrasound.
|
4 to 6 weeks after embryo transfer
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Post-processing sperm DNA fragmentation index (DFI, %)
Zeitfenster: Immediately after sperm preparation on the day of oocyte retrieval
|
Evaluated using the LensHooke® R11 Plus assay
|
Immediately after sperm preparation on the day of oocyte retrieval
|
|
Blastocyst rate and good-quality blastocysts rate
Zeitfenster: Day 5 to Day 6 after ICSI
|
Evaluated according to Gardner's criteria and classified following Munné et al. (2019)
|
Day 5 to Day 6 after ICSI
|
|
Euploidy rate.
Zeitfenster: Within 2 weeks after blastocyst biopsy
|
Assessed via preimplantation genetic testing for aneuploidy (PGT-A) using next-generation sequencing (NGS).
|
Within 2 weeks after blastocyst biopsy
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MICEH-2026-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .